Merck vs Pfizer

MRK · PFE

In fiscal year 2025 Merck reported $65.0B in revenue against Pfizer's $62.6B, 1.04× as much.

Merck vs Pfizer
Measure	MRK	PFE	Gap
Revenue	$65.0B	$62.6B	×1.04
Cost of revenue	$16.4B	$16.1B	×1.02
Operating income	$21.1B	$7.5B	×2.80
Net income	$18.3B	$7.8B	×2.35
EPS (diluted)	7.28	1.36	×5.35
Total assets	$137B	$208B	×1.52
Shareholders' equity	$52.6B	$86.5B	×1.64
Cash	$14.6B	$1.1B	×12.75
Long-term debt	$46.8B	$61.6B	×1.32
Net margin	28.1%	12.4%	×2.26
Operating margin	32.4%	12.0%	×2.70
Operating cash flow	$16.5B	$11.7B	×1.41
Capital expenditure	$4.1B	$2.6B	×1.56
Free cash flow	$12.4B	$9.1B	×1.36
R&D expense	$15.8B	$10.4B	×1.51
Income tax expense	$2.8B	−$266M	—
Share buybacks	$5.1B	$0	—

The larger of the two figures is in bold. Larger is not automatically better: on debt, cost and tax a bigger number is simply a bigger number. This site reports the figures and leaves the judgement to you.

Revenue, year by year

Merck · 2016–2025

Pfizer · 2016–2025

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Merck vs Pfizer |url=https://companiesranked.com/en/compare/merck-vs-pfizer |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Merck vs Pfizer. CompaniesRanked. https://companiesranked.com/en/compare/merck-vs-pfizer

BibTeX

@misc{companiesranked-en-compare-merck-vs-pfizer-2026,
  author       = {{CompaniesRanked}},
  title        = {{Merck vs Pfizer}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/compare/merck-vs-pfizer}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Merck · Pfizer →